Related Experiment Video
Updated: May 23, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors
Junxing Shi1, Longhu Zhou, Franck Amblard
1RFS Pharma, LLC, 1860 Montreal Road, Tucker, GA 30084, USA.
Abstract:
NS5A inhibitors are a new class of direct-acting antiviral agents which display very potent anti-HCV activity in vitro and in humans. Rationally designed modifications to the central biphenyl linkage of a known NS5A series led to selection of several compounds that were synthesized and evaluated in a HCV genotype 1b replicon. The straight triphenyl linked compound 11a showed similar anti-HCV activity to the clinical compound BMS-790052 and a superior cytotoxicity profile in three different cell lines, with an EC(50) value of 26 pM and a therapeutic index of over four million in an HCV replicon assay. This triphenyl analog warrants further preclinical evaluation as an anti-HCV agent.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Subviral Agents
Inhibitors of Bacterial DNA Synthesis

